Investors Sue Fertility Treatment Co. Following FDA Letter

Law360, New York (September 16, 2013, 6:00 PM EDT) -- OvaScience Inc. and its top brass were hit with a putative shareholder class action Monday following a company announcement that it was suspending trials of its flagship fertility treatment because of drug classification concerns by the U.S. Food and Drug Administration.

Cambridge, Mass.-based OvaScience was sued in Massachusetts federal court by Meriam Ratner, an investor who claimed the life sciences company misrepresented that its fertility treatment Augment would not need FDA approval to be tested or marketed. The FDA announced on Sept. 10 that the treatment...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Ratner v. OvaScience, Inc. et al


Case Number

1:13-cv-12286

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

William G. Young

Date Filed

September 16, 2013

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.